The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Black Health Matters (BHM), the nation's leading health equity platform dedicated to improving the health outcomes of Black ...

Dupilumab treatment of atopic dermatitis resulted in long-term skin improvements linked to changes in skin’s the molecular composition.

Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...

Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...